Coexisting severe mental illness and substance misuse (QS188)Product type:Quality standardPublished: 20 August 2019
Coexisting severe mental illness and substance misuse: community health and social care services (NG58)Product type:GuidanceProgramme:NICE guidelinePublished: 30 November 2016
Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings (CG120)Product type:GuidanceProgramme:Clinical guidelinePublished: 23 March 2011
Drug misuse in over 16s: opioid detoxification (CG52)Product type:GuidanceProgramme:Clinical guidelinePublished: 25 July 2007
Drug misuse in over 16s: psychosocial interventions (CG51)Product type:GuidanceProgramme:Clinical guidelinePublished: 25 July 2007
Drug misuse prevention: targeted interventions (NG64)Product type:GuidanceProgramme:NICE guidelinePublished: 22 February 2017
Methadone and buprenorphine for the management of opioid dependence (TA114)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Naltrexone for the management of opioid dependence (TA115)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 January 2007
Needle and syringe programmes (PH52)Product type:GuidanceProgramme:Public health guidelinePublished: 26 March 2014
Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)Product type:AdviceProgramme:Evidence summaryPublished: 14 February 2019